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Soft tissue sarcomas constitute a heterogeneous category of
neoplasms composed mostly of uncommon tumours of
different histology, different biology, and different outcome.
Thirty years ago, the diagnosis of these neoplasms was
mainly based on morphology coupled with some classical
histochemical stains such as periodic acid-Schiff, reticulin,
and trichrome stains. In the last 15 years, thanks to the
substantial development of immunohistochemistry, cytoge-
netics and molecular genetic analysis significant improve-
ments have been made regarding the classification and
diagnosis of these tumors, with direct implications for
clinical management and prognosis [1, 2]. Many new
entities were recognized of which desmoplastic small round
cell tumor and intimal sarcomas are examples. Other
sarcoma entities gradually disappeared or lost in importance
(e.g., the so-called malignant fibrous histiocytoma [3],
hemangiopericytoma [4], and fibrosarcoma categories).
During the same period of time, molecular ancillary
techniques (including a vast array of polymerase chain
reaction-based techniques, fluorescence in situ hybridiza-
tion (FISH), conventional and array-based comparative
genomic hybridization, expression arrays, direct genome
sequencing, and DNA methylation analysis to name a few)
allowed detailed analysis of these tumors and the resulting
data facilitated better understanding of their biology
(Fig. 1). In addition, thanks to improvements in nucleic
acid preservation and isolation, many molecular techniques
provided new parameters important for diagnostics and/or
prognosis and were modified to be applicable on formalin-
fixed, paraffin-embedded material (e.g., FISH, polymerase
chain reaction-based techniques). This is all condensed in a
substantial revision of the World Health Organization
classification which combined histology with genetics [2].
Methodological advances thus allowed better understanding
of biology, within turn novel classifications based upon
new histogenetic concepts and robust diagnostic methods.
This review issue focuses on the pathobiology of soft
tissue sarcomas. In the introductory paper, Bovée and
Hogendoorn introduced to the reader the most significant
molecular acquisitions that occurred in the domain of
sarcomas and their implications for the patient in terms of
diagnosis, prognosis, and clinical management [5]. The
genomic characteristics of soft tissue sarcomas are exposed
in an article of Mertens and coworkers [6]. Here, the
authors discuss how the genomic characterization of soft
tissue sarcomas has not only provided cell biologists with
decisive information on the parts of the genome that may
harbor genes that are essential for tumor development, but
also given the clinicians involved in the management of
these patients a valuable diagnostic tool. Beck et al. share
with us the “state of the art” of gene expression profiling in
soft tissue sarcomas and how this technique has led to
advancements in the understanding of sarcoma pathobiol-
ogy, the identification of clinically useful biomarkers, and
the refinement of sarcoma classification schemes, with
hopefully significant benefits to patients [7].
There are two intriguing and highly relevant questions in
sarcoma pathobiology: the first one is “why do some people
develop sarcomas?” and the second is “from which cells do
sarcomas develop?”. Recent studies in model systems as
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these questions and undoubtedly, in the years to come,
much of the secrets of mesenchymal stem cells, how they
differentiate and how dysregulation of proliferation and
differentiation in this system leads to which type of
sarcoma [8–15].
Roughly, soft tissue sarcomas can be divided in two
categories, those with simple karyotypes and those with
complex karyotypes [16]. Of the soft tissue sarcomas (with
relatively simple karyotypes), 15-20% bear specific recip-
rocal translocations which can be used as diagnostic
markers. Some others are characterized by specific somatic
mutations (e.g., KIT and platelet-derived growth factor
receptor alpha in gastrointestinal stromal tumor (GIST)
[17]) or specific amplifications (e.g., MDM2 and CDK4
amplification in the well-differentiated/dedifferentiated
liposarcoma category [18]).
For the purposes of this review, sarcomas with specific
translocations have been separated into two groups, those
involving the Ewing’s sarcoma (EWS) gene and those that
do not involve the EWS gene. Sarcomas involving EWS
translocations (e.g., Ewing’s sarcoma, desmoplastic small
round cell tumor, etc.) are reviewed by Dei Tos and Romeo
[19], whereas genetic and clinicopathological features of
soft tissue sarcomas with non EWS translocations (e.g.,
synovial sarcoma, alveolar rhabdomyosarcoma, etc.) are
presented in a comprehensive way by Fisher [20].
In the last 10 years, improvements have been accom-
plished regarding the diagnosis and pathobiology of well-
differentiated/dedifferentiated liposarcomas. Coindre and
coworkers summarize for us the most significant advances
that occurred in this domain, including the discovery of
new promising therapeutic targets [21].
Soft tissue sarcomas with complex karyotypes account
for about 50% of sarcomas. This sarcoma category includes
most of spindle cell/pleomorphic sarcomas (myxofibrosar-
coma, pleomorphic liposarcoma, etc.) as well as leiomyo-
sarcomas, malignant peripheral nerve sheath tumors, and
many other neoplasm’s. Guillou and Aurias review their
cytogenetic, molecular genetics, and main clinicopathologic
characteristics [22]. Most recently, progress in the field of
protein chemistry led to a new conceptual approach in order
to try to unravel aspecific terms like myxoid matrix (see
also Fig. 1). Attempts were made to characterize this matrix
[23, 24] which turned out to be heterogeneous at the protein
level, while morphologically the hallmark of an array of
tumor types [25]. Willems et al. discuss the usefulness of
such an approach for myxoid matrix containing tumors if
explored [26]. Dr. Liegl and coworkers finally discuss the
progress made in the understanding of the pathobiology,
morphologic evaluation and mechanisms of resistance to
tyrosine kinase inhibition in GIST [27]. Gist is one of the
examples in oncopathology where the understanding of the
genetics of the tumour have lead to major changes in
treatment following the development of specific tyrosine
kinase blockers [28]. Now we have reached the moment
that the subsequent resistant mechanisms which develop in
the course of the treatment are of keen interest for
Fig. 1 Unraveling soft tissue
tumors from macroscopy via
histology to proteinprofiling and
genetics: Macroscopic image of
a myxoid soft tissue tumour
characterized by its abundant
jelly (“myxoid”) extracellular
matrix on cut surface; histology
of grade I myxofibrosarcoma
showing sparse tumour cells
with slight nuclear atypia in a
background of myxoid extracel-
lular matrix with curvilinear
bloodvessels (×400); imaging
mass spectrometry on a tissue
slide of grade I myxofibrosar-
coma illustrating the heteroge-
neity in lipid profiles related to
their spatial distribution; and
combined binary ratio fluores-
cence in situ hybridization of
grade III myxofibrosarcoma
with numeric and structural
karyotypic aberrations
108 Virchows Arch (2010) 456:107–109molecular pathologist and of importance for the patients
which have gained years of live quality after treatment of
this in the past so aggressive tumor.
For those interested in sarcomas, these are exciting
times. We are getting closer to understanding their biology;
our diagnoses are better and grow closer to what clinicians
need to adequately treat patients. Much remains to be done.
We hope that this review issue on the pathobiology of soft
tissue sarcomas meets the expectations of the readers of
Virchows Archiv. The guest editors warmly thank all the
contributors for their effort, willingness, and invaluable
input to this work.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Hogendoorn PCW, Collin F, Daugaard S et al (2004) Changing
concepts in the pathological basis of soft tissue and bone sarcoma
treatment. Eur J Cancer 40:1644–1654
2. Fletcher CDM, Unni KK, Mertens F (2002) WHO classification
of tumours. Pathology and genetics of tumours of soft tissue and
bone. IARC Press, Lyon
3. Fletcher CDM (1992) Pleomorphic malignant fibrous histiocy-
toma: fact or fiction? A critical reappraisal based on 159 tumors
diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213–228
4. Fletcher CDM (1994) Haemangiopericytoma—a dying breed?
Reappraisal of an ‘entity’ and its variants: a hypothesis. Curr
Diagn Pathol 1:19–23
5. Bovee JVMG, Hogendoorn PCW (2010) Molecular pathology of
sarcomas: concepts and clinical implications. Virchows Arch.
doi:10.1007/s00428-009-0828-5
6. Mertens F, Panagopoulos I, Mandahl N (2010) Genomic charac-
teristics of soft tissue sarcomas. Virchows Arch. doi:10.1007/
s00428-009-0736-8
7. Beck AH, West RB, Van de Rijn M (2010) Gene expression
profiling for the investigation of soft tissue sarcoma pathogenesis
and the identification of diagnostic, prognostic, and predictive
biomarkers. Virchows Arch. doi:10.1007/s00428-009-0774-2
8. Mohseny AB, Szuhai K, Romeo S et al (2009) Osteosarcoma
originates from mesenchymal stem cells in consequence of aneu-
ploidization and genomic loss of Cdkn2. J Pathol 219:294–305
9. Cironi L, Provero P, Riggi N et al (2009) Epigenetic features of
human mesenchymal stem cells determine their permissiveness for
induction of relevant transcriptional changes by SYT-SSX1. PLoS
ONE 4:e7904
10. Riggi N, Cironi L, Provero P et al (2005) Development of
Ewing’s sarcoma from primary bone marrow-derived mesenchy-
mal progenitor cells. Cancer Res 65:11459–11468
11. Riggi N, Cironi L, Suva ML et al (2007) Sarcomas: genetics,
signalling, and cellular origins. Part 1: the fellowship of TET. J
Pathol 213:4–20
12. Riggi N, Cironi L, Provero P et al (2006) Expression of the FUS-
CHOP fusion protein in primary mesenchymal progenitor cells
gives rise to a model of myxoid liposarcoma. Cancer Res
66:7016–7023
13. Riggi N, Suva ML, Suva D et al (2008) EWS-FLI-1 expression
triggers a Ewing’s sarcoma initiation program in primary human
mesenchymal stem cells. Cancer Res 68:2176–2185
14. Suva ML, Cironi L, Riggi N et al (2007) Sarcomas: genetics,
signalling, and cellular origins. Part 2: TET-independent fusion
proteins and receptor tyrosine kinase mutations. J Pathol 213:117–
130
15. Suva ML, Riggi N, Stehle JC et al (2009) Identification of cancer
stem cells in Ewing’s sarcoma. Cancer Res 69:1776–1781
16. Ladanyi M (1995) The emerging molecular genetics of sarcoma
translocations. Diagn Mol Pathol 4:162–173
17. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function
mutations in c-kit in human gastrointestinal stromal tumors.
Science 279:577–580
18. Dei Tos AP (2001) Lipomatous tumours. Curr Diagn Pathol 7:8–16
19. Romeo S, Dei Tos AP (2010) Soft tissue tumors associated with
EWSR1 translocation. Virchows Arch. doi:10.1007/s00428-009-
0854-3
20. Fisher C (2010) Soft tissue sarcomas with non-EWS trans-
locations: molecular genetic features and pathologic and
clinical correlations. Virchows Arch. doi:10.1007/s00428-009-
0776-0
21. Coindre JM, Pedeutour F, Aurias A (2010) Well-differentiated and
dedifferentiated liposarcomas. Virchows Arch. doi:10.1007/
s00428-009-0815-x
22. Guillou L, Aurias A (2010) Soft tissue sarcomas with complex
genomic profiles. Virchows Arch. doi:10.1007/s00428-009-
0853-4
23. Willems SM, Schrage YM, Baelde JJ et al (2008) Myxoid
tumours of soft tissue: the so-called myxoid extracellular matrix
is heterogeneous in composition. Histopathology 52:465–474
24. Willems SM, Mohseny AB, Balog C et al (2009) Cellular/
intramuscular myxoma and grade I myxofibrosarcoma are
characterized by distinct genetic alterations and specific
composition of their extracellular matrix. J Cell Mol Med
7:1301
25. Graadt van Roggen JF, Hogendoorn PCW, Fletcher CDM (1999)
Myxoid tumours of soft tissue. Histopathology 35:291–312
26. Willems SM, Wiweger M, Frans Graadt van Roggen J et al.
(2010) Running GAGs: myxoid matrix revisited. What’si ni t
for the pathologist? Virchows Arch. doi:10.1007/s00428-009-
0822-y
27. Liegl-Atzwanger B, Fletcher JA, Fletcher CMD (2010) Gas-
trointestinal stromal tumors. Virchows Arch. doi:10.1007/
s00428-010-0891-y
28. Verweij J, van Oosterom A, Blay JY et al (2003) Imatinib
mesylate (STI-571 Glivec(R), Gleevec) is an active agent for
gastrointestinal stromal tumours, but does not yield responses in
other soft-tissue sarcomas that are unselected for a molecular
target. Results from an EORTC Soft Tissue and Bone Sarcoma
Group phase II study. Eur J Cancer 39:2006–2011
Virchows Arch (2010) 456:107–109 109